




## Life Settlement Assets PLC – Ordinary Share A

## **Investment Objective**

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

## **Estimated Performance**



## Commentary

# 1.5% Management Fee

**Investment Terms** 

Estimated NAV (USD) 99 292 194

NAV/Share 2.1848

Insurance companies can underwrite more efficiently and cost-effectively using artificial intelligence, creating a substantial benefit by freeing up underwriters to focus on more complex and heterogenous risks, where human judgement is more valuable. Cytora, a U.K. startup that developed an AI-powered solution for commercial insurance underwriting, claims that they can shorten the seven-day underwriting process to 30 seconds via its API. This enables insurers to underwrite programmatically and build workflows that provide faster and more accurate decisions.

Share Class A had a positive performance of 0.27% for the month of March. Nine maturities for a total death benefit of \$ 0.3M were registered in the HIV segment; three maturities were registered in the non-HIV segment, for a coverage of \$ 1.7M. In addition, a small portfolio of fractionals, to which the trust was overwhelmingly already exposed to, was added in order to prevent any undue lapsing. The flat performance is mainly due to high valuation of non-HIV policies.

Number Of Policies		Death Benefits (USD)	Matured Policies YTD		Maturities YTD (USD)
4 601		451 627 081	32		17 676 670
Trust Investment Manager	Acheron Capital Ltd.		Company Secretary	Maitland Administration Services Limited	
Administrator	Compagnie Européenne de Révision		ISIN Ticker	GB00BF1Q4B05 LSAA	
Auditor	Grant Thornton UK LLP		Info	life@ache +44 207 2	eroncapital.com 158 5990




HIV


Non-HIV

300k+









2,200

2,000

1,800

1,600

1,400

1,200

1,000


800


600 400

4 of policies ( 00 (

#

**Distribution by Insurance Company** 






(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount. (2)Distribution by issue dates reflects the time since the life insurance policy was issued. Source of Data: Acheron Capital Ltd unless otherwise stated.


## March 2019





### **Maturities March 2019**

Number of policies matured in March 2019	12
Corresponding number of insured	7
Total death benefit in March 2019(US\$)	2 020 558
Valuation of Matured policies in Book (US\$)	486 665



## Premiums Situation (US\$)<sup>(1)</sup>

Servicers Premiums Projection as of Beginning 2019	\$ 11.6M
Mortality Adjusted Premiums Projection Beginning 2019	\$ 11.1M
Estimated COI Net of Mortality Beginning 2019	\$ 10.1M

## Top 10 Coverage

Insured	Face (millions)	Total Face (millions)	Age (ALB)	Expiration Age*
1	10.2	10.2	98	100
2	3.8	3.8	93	100
3	1.9/1.4	3.3	95	100/100
4	2.8	2.8	78	100
5	1.2/0.9/0.6	2.7	76	121/100/100
6	1.2/0.8/0.4/0.1/0.1/0.1	2.7	90	100/100/100/95/100/115
7	2.7	2.7	94	100
8	1.3/1.0	2.3	95	100/115
9	2.0	2.0	92	100
10	1.2/0.4/0.1/0.1/0.1	1.9	91	100/100/100/100/100

## Cash Situation (US\$)<sup>(1)</sup>

Cash at hand and similar	\$ 12.9M
Gross Cash in Policies <sup>(2)</sup> (estimated as of end 2018)	\$ 43.3M
Loan on Cash in Policies (estimated as of end 2018)	\$ 21.7M
Net Cash in Policies <sup>(2)</sup> (estimated as of end 2018)	\$ 21.6M
Maturities to be received	\$ 17.2M

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Cash for ABC policies not included. Surrender charge included.

\*In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.